Patents Assigned to Medarex, L.L.C.
-
Patent number: 9062111Abstract: A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response is elicited in the patient or a pre-determined maximum dosage is reached.Type: GrantFiled: December 22, 2011Date of Patent: June 23, 2015Assignee: MEDAREX, L.L.C.Inventors: Geoffrey M. Nichol, Israel Lowy
-
Publication number: 20150165025Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.Type: ApplicationFiled: November 18, 2014Publication date: June 18, 2015Applicants: Medarex, L.L.C., Ono Pharmaceutical Co., LTD.Inventors: Alan J. KORMAN, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
-
Patent number: 8981071Abstract: This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided.Type: GrantFiled: December 22, 2010Date of Patent: March 17, 2015Assignees: Amgen, Inc., Medarex, L.L.C.Inventors: Gerald Siu, Wenyan Shen, Steven K. Yoshinaga, Haichun Huang
-
Patent number: 8945546Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: GrantFiled: May 23, 2012Date of Patent: February 3, 2015Assignee: Medarex, L.L.C.Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
-
Publication number: 20140335099Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.Type: ApplicationFiled: March 5, 2014Publication date: November 13, 2014Applicants: Amgen Inc., Medarex, L.L.C.Inventors: Brian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliott
-
Publication number: 20140328833Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.Type: ApplicationFiled: May 6, 2014Publication date: November 6, 2014Applicants: Medarex, L.L.C., Ono Pharmaceutical Co., LTD.Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
-
Patent number: 8865875Abstract: The present invention provides antibodies (e.g., IgG antibodies) having C-terminal cysteine-containing extensions that facilitate antibody conjugation to a partner molecule (e.g. a drug, toxin, marker molecule, protein, radioisotope, or other therapeutic agent). Methods of making, screening and selecting the antibodies of the invention are provided.Type: GrantFiled: August 19, 2008Date of Patent: October 21, 2014Assignee: Medarex, L.L.C.Inventors: Jie Liu, David King
-
Patent number: 8835712Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.Type: GrantFiled: September 9, 2010Date of Patent: September 16, 2014Assignees: Medarex, L.L.C., Kyowa Hakko Kirin Co., Ltd.Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
-
Patent number: 8828393Abstract: Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR).Type: GrantFiled: March 17, 2011Date of Patent: September 9, 2014Assignee: Medarex, L.L.C.Inventors: Lesley B. Pickford, Christopher R. Bebbington, Geoffrey T. Yarranton, David King
-
Publication number: 20140234331Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.Type: ApplicationFiled: April 28, 2014Publication date: August 21, 2014Applicant: Medarex, L.L.C.Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
-
Patent number: 8802632Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:Type: GrantFiled: January 29, 2013Date of Patent: August 12, 2014Assignee: Medarex, L.L.C.Inventors: Heng Cheng, Sanjeev Gangwar, Qiang Cong
-
Patent number: 8784815Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.Type: GrantFiled: November 1, 2012Date of Patent: July 22, 2014Assignee: Medarex, L.L.C.Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
-
Patent number: 8779105Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.Type: GrantFiled: August 15, 2011Date of Patent: July 15, 2014Assignee: Medarex, L.L.C.Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bing Chen, Josephine M. Cardarelli, Haichun Huang
-
Patent number: 8772543Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:Type: GrantFiled: January 29, 2013Date of Patent: July 8, 2014Assignee: Medarex, L.L.C.Inventors: Heng Cheng, Sanjeev Gangwar, Qiang Cong, Qian Zhang
-
Patent number: 8772542Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:Type: GrantFiled: January 29, 2013Date of Patent: July 8, 2014Assignee: Medarex, L.L.C.Inventors: Heng Cheng, Sanjeev Gangwar, Qiang Cong
-
Patent number: 8765415Abstract: The present invention provides a method of increasing protein production in a cell culture by growing cells that produce the protein (e.g., the growth phase) in a perfusion cell culture to a high cell density (i.e., at least above about 40×106 cells/N mL) and then switching to a protein production phase, wherein the cells are cultured in a fed-batch cell culture. The present invention further provides a method for clarifying a protein from a cell culture by adjusting the pH of the cell culture to below neutral pH (i.e., below a pH of 7) and settling the cell culture, such that the cell culture separates to form a supernatant layer and a cell-bed layer, wherein the protein is in the supernatant layer.Type: GrantFiled: November 17, 2010Date of Patent: July 1, 2014Assignee: Medarex, L.L.C.Inventors: Alahari Arunakumari, Xiao-Ping Dai, Javier Garcia, Richard P. Martel
-
Publication number: 20140179904Abstract: The present invention provides methods for purifying proteins. In particular, the methods employ a two-step non-affinity chromatography process without the use of an in-process tangential flow filtration step.Type: ApplicationFiled: February 28, 2014Publication date: June 26, 2014Applicant: Medarex, L.L.C.Inventors: Alahari Arunakumari, Gisela Maria Marques Ferreira
-
Patent number: 8758757Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.Type: GrantFiled: December 20, 2010Date of Patent: June 24, 2014Assignee: Medarex, L.L.C.Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
-
Publication number: 20140134180Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.Type: ApplicationFiled: November 7, 2013Publication date: May 15, 2014Applicant: MEDAREX, L.L.C.Inventors: ALAN J. KORMAN, MARK J. SELBY, LI-SHENG LU, ALISON J. WITTE, HAICHUN HUANG
-
Patent number: 8722870Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: GrantFiled: June 4, 2013Date of Patent: May 13, 2014Assignee: Medarex, L.L.C.Inventors: Alison J. Witte, Denise Williams, Josephine M. Cardarelli, David King, David B. Passmore